“The outcome reflects our continued focus on quality excellence and regulatory compliance, reinforcing our commitment to delivering safe and effective medicines to patients worldwide,” Nilesh Gupta, the managing director of Lupin, said.
On another note, the pharma major on Wednesday said the GST department of Maharashtra had initiated an inspection and search at its office. It said it was cooperating with authorities and the proceedings had no impact on its financials, operations and other activities.Earlier this week, Lupin received the USFDA’s approval for its abbreviated new drug application (ANDA) for Brivaracetam oral solution in the 10mg/ml strength. It is indicated for the treatment of partial-onset seizures in patients aged one month and older.
Lupin shares were up 0.2% at ₹2,328.7 apiece around 1.55 pm. The stock has gained 22.5% in the last six months.
Also Read: Sarda Energy shares gain 8% after SC dismisses plea of unsuccessful bidders for SKS Power acquisition
